The biotech sector continues to pull more than its weight in developing new medicines, a trend that, even in the midst of a global pandemic, has drawn vast amounts of new capital to fund pipeline growth in areas ranging from cell and gene therapy to the microbiome. This year has already broken the all-time record for IPO placements and valuations remain high even for those companies still seeking to launch their first marketed product. Still, small biotech must compete for visibility and resources against the global established players in big pharma, particularly for those with a therapeutic focus on medicines outside the current frenzied search for solutions to the coronavirus pandemic.

To mark the Prix Galien USA’s upcoming October 26 “Week of Discovery and Celebration on the Frontiers of Medical Innovation,” distinguished members of the USA Galien Awards Committee will chair three webinars highlighting each of the 23 nominee products they have selected for the best Biotechnology category.

These virtual expert panelist exchanges will offer the opportunity for webinar participants to assess the current state of innovation in biotech, covering key aspects of clinical progress and differentiation; the ways that patient care is now being conducted outside traditional delivery settings; and the next wave of promising breakthrough technologies, including their transformative – and potentially disruptive – effect on health care productivity and outcomes worldwide.